- Screener
- Securities US
- Emergent BioSolutions Inc
Emergent BioSolutions Inc
$4.540
-$0.070
-1.52%
21 Apr 20:00
$1.824
$15.100
52 weeks low/high
Market sentiment
Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).
Overall assessment
weak bullish sentiment is waning
3day with a yield of-0.22%
Long
100.00%Short
0.00%| Index | Bulls | Bears |
|---|---|---|
Confidence | — | |
Support | — | |
Cash flows | — |
Technical analysis
- Trend ClassTurning down
- Trend PowerMedium strength trend
- PatternDescending Wedge
- EMA-20Bearish reversal2025-02-06 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
- EMA-50Bearish reversal2025-02-11 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
- EMA-100Bearish reversal2025-02-18 the price crossed down the moving average line and demonstrates a strong downside trend.
- StochasticBullishThe stochastic indicator is in overbought territory and it grows. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.
- RSIBearish recoveryRSI indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: entrance to the overbought zone.
- MACDBearish WeakeningOscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.
- Candle pattern typeDojiIs formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | 1.33% | 4.11% | $4.490 | $4.690 | 1.88M |
| Week | 2.21% | 1.96% | $4.340 | $4.690 | 9.47M |
| Month | -18.16% | 0.15% | $4.020 | $5.930 | 80.21M |
| 3 Months | -54.15% | 5.36% | $4.020 | $11.980 | 370.06M |
| 6 Months | -54.08% | 19.73% | $4.020 | $12.730 | 896.39M |
| Year | 129.47% | 0.64% | $1.824 | $15.100 | 3.58B |
| 3 years | -88.03% | 56.01% | $1.420 | $41.290 | 7.85B |
| 5 years | -93.00% | 76.51% | $1.420 | $137.610 | 23.03B |
| All time | -11.58% | 54.85% | $1.420 | $137.610 | 23.26B |
Volatility
| EBS | By industry | |
|---|---|---|
| Yesterday | 9.28% | 1.03% |
| Week | 12.92% | 1.76% |
| Month | 80.05% | 9.54% |
| 3 Months | 88.73% | 20.61% |
| 6 Months | 126.57% | 29.79% |
| Year | 141.00% | 41.76% |
| 3 years | 201.49% | 90.20% |
| 5 years | 219.14% | 117.61% |
| All time | — | — |
- Sortino
- 0.92
- Sharpe
- 1.01
- Sterling
- 4.47
- Liquidity index
- 5.05
- Alpha
- -0.00474
- Beta
- 1.71
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$251.04M
Capitalization
54.34M
Shares outstanding
Health Care
Sector
Biotechnology
Industry
US29089Q1058
ISIN
1
Lot size
Mr. Robert G. Kramer Sr.
CEO
Website
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.